The gain of function of p53 mutant p53s in promoting tumorigenesis by cross-talking with H-RasV12

International Journal of Biological Sciences

Volumn 8, Issue 5, 2012, Pages 596-605

  Jia, Shuting ^a   Zhao, Lanjun ^a   Tang, Wenru ^a   Luo, Ying ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cross talk; DNA damage response; Gain of function; P53 mutant; Ras; Tumorigenesis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; PROTEIN P53;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE CHECKPOINT; CELL TRANSFORMATION; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN; MOUSE; MOUSE MUTANT; MUTATION; ONCOGENE RAS; TRANSCRIPTION INITIATION;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENES, RAS; HUMANS; MICE; MICE, SCID; MUTATION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 84863773500     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.4176     Document Type: Article

References (35)

1. Petitjean A, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat, 2007. 28(6): 622-9.
2. Walker D. R, et al. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene, 1999. 18(1): 211-8.
3. Brosh R and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer, 2009. 9(10): 701-13.
4. Joerger A. C, Ang H. C, and Fersht A.R. Structural basis for under-standing oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A, 2006. 103(41): 15056-61.
5. Laud P. R, et al. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev, 2005. 19(21): 2560-70.
6. Martin A. C, et al. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat, 2002. 19(2): 149-64.
7. Kato S, et al. Understanding the function-structure and func-tion-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A, 2003. 100(14): 8424-9.
8. Mathe E, et al. Predicting the transactivation activity of p53 mis-sense mutants using a four-body potential score derived from De-launay tessellations. Hum Mutat, 2006. 27(2): 163-72.
9. Firestein G. S, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A, 1997. 94(20): 10895-900.
10. Han Z, et al. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum, 1999. 42(6): 1088-92.
11. Jacks T, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol, 1994. 4(1): 1-7.
12. Olivier M, et al. Recent advances in p53 research: an interdiscipli-nary perspective. Cancer Gene Ther, 2009. 16(1): 1-12.
13. Murphy K. L, Dennis A. P, and Rosen J.M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J, 2000. 14(14): 2291-302.
14. Trent J, et al. Evidence for rearrangement, amplification, and ex-pression of c-myc in a human glioblastoma. Proc Natl Acad Sci U S A, 1986. 83(2): 470-3.
15. Tanaka K, et al. Amplification of c-oncogene MYC and point mu-tation of N-RAS oncogene point mutation in acute myelocytic leu-kemias with double minute chromosomes. Leukemia, 1993. 7(3): 469-71.
16. Di Micco R, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 2006. 444(7119): 638-42.
17. Campomenosi P, et al. p53 mutants can often transactivate pro-moters containing a p21 but not Bax or PIG3 responsive elements. Oncogene, 2001. 20(27): 3573-9.
18. Brachmann R. K, et al. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J, 1998. 17(7): 1847-59.
19. Nikolova P. V, et al. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A, 1998. 95(25): 14675-80.
20. Nikolova P. V, et al. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J, 2000. 19(3): 370-8.
21. Khoo K. H, Mayer S, and Fersht A.R. Effects of stability on the bio-logical function of p53. J Biol Chem, 2009. 284(45): 30974-80.
22. Serrano M, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 1997. 88(5): 593-602.
23. Tremain R, et al. Defects in TGF-beta signaling overcome senes-cence of mouse keratinocytes expressing v-Ha-ras. Oncogene, 2000. 19(13): 1698-709.
24. Buganim Y, et al. p53 Regulates the Ras circuit to inhibit the ex-pression of a cancer-related gene signature by various molecular pathways. Cancer Res, 2010. 70(6): 2274-84.
25. Hingorani S. R, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005. 7(5): 469-83.
26. Vivanco I and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2002. 2(7): 489-501.
27. Nogueira V, et al. Akt determines replicative senescence and oxi-dative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell, 2008. 14(6): 458-70.
28. Dolado I and Nebreda A.R. AKT and oxidative stress team up to kill cancer cells. Cancer Cell, 2008. 14(6): 427-9.
29. Johnson T. M, et al. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic le-thality. Nat Genet, 2005. 37(2): 145-52.
30. Reczek E. E, et al. Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res, 2003. 1(14): 1048-57.
31. Martinez-Gac L, et al. Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle con-trol by phosphoinositide 3-kinase and forkhead. Mol Cell Biol, 2004. 24(5): 2181-9.
32. Iwakuma T, et al. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene, 2004. 23(46): 7644-50.
33. Bruins W, et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol, 2004. 24(20): 8884-94.
34. Wu W. S, et al. Slug antagonizes p53-mediated apoptosis of hema-topoietic progenitors by repressing puma. Cell, 2005. 123(4): 641-53.
35. Chang S, et al. Telomere-based crisis: functional differences be-tween telomerase activation and ALT in tumor progression. Genes Dev, 2003. 17(1): 88-100.